Baptist Hospitals of Southeast Texas, Beaumont
Fangzheng Yuan , Ahmed Abdelhakeem , Samantha Blevins , Chelsey Peters , Susan E. Whalen , Ernest Clayton Hymel
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has changed the delivery of cancer care and may have impacted the treatment outcomes. This study described the preliminary outcomes in non-metastatic breast cancer (BC) patients before and during the COVID-19 pandemic. Methods: This retrospective study included adult patients newly diagnosed with non-metastatic BC at two community cancer centers in southeast Texas. Patients diagnosed from 1/2018-10/2018 were included in the control group. Patients diagnosed from 4/2020-1/2021 were included in the COVID-19 group. The key outcomes were progression free survival (PFS), overall survival (OS), breast conserving surgery (BCS) rate, pathological complete response (PCR) rate, and time to treatment initiation (TTI). Results: The study included 74 patients (Table). The proportion of patients with self-detected BC was numerically higher in the COVID-19 group (55%) compared to the control group (36%), although this was not statistically significant (P = 0.09). The median follow-up periods were 38 (IQR: 36-43) months in the control group and 15 (IQR: 13-17) months in the COVID-19 group. No significant difference was observed in PFS (P = 0.74), with 1-year PFS of 93% (95%CI: 80%-98%) in the control group and 100% in the COVID-19 group. No significant difference was observed in OS (p = 0.22), with 1-year OS of 98% (95%CI 85%-100%) in the control group and 100% in the COVID-19 group. No significant difference was observed in TTI between control (51 days) and COVID-19 groups (52 days) (95%CI: -14 to 13; P = 0.91). Among patients who received neoadjuvant systemic therapy and surgery, BCS rates were 29% (5/17) in the control group and 50% (5/10) in the COVID-19 group (P = 0.42). Among patients who had triple negative or HER2 positive BC and received neoadjuvant systemic therapy and surgery, PCR rates were 57% (4/7) in the control group and 33% (1/3) in the COVID-19 group. Conclusions: Although total patient volume decreased during the COVID-19 pandemic, no significant difference was observed in clinical outcomes when comparing patients diagnosed with non-metastatic BC during and prior to the pandemic. Ongoing monitoring with a larger study population and longer follow-up period will help to elucidate the long-term impact of COVID-19 on BC treatment.
Control (n = 45) | COVID-19 (n = 29) | |
---|---|---|
Age in years, mean (IQR) | 68 (58-74) | 63 (51-73) |
Female, n (%) | 43 (96) | 29 (100) |
Clinical stage, n (%) | ||
0 | 5 (11) | 3 (10) |
1 | 19 (42) | 11 (38) |
2 | 12 (27) | 12 (41) |
3 | 8 (18) | 3 (10) |
Unknown | 1 (2) | 0 (0) |
Initial treatment, n (%) | ||
Surgery | 27 (60) | 18 (62) |
Systemic therapy | 18 (40) | 10 (34) |
Endocrine therapy | 0 (0) | 1 (3) |
ER/PR positive, n (%) | 41 (91) | 26 (90) |
HER2 positive, n (%) | 9 (20) | 3 (10) |
Triple negative, n (%) | 3 (7) | 3 (10) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Isabel Miras
2024 ASCO Annual Meeting
First Author: Bilja Kurian Sajith
2023 ASCO Annual Meeting
First Author: Zefei Jiang
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Bahar Laderian